Rapport Therapeutics, Inc. (RAPP) stock
RAPPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$26.15+0.30 (+1.16%)
Close on Nov 13, 2026Market cap $1.25BP/E –Yield –
Rapport Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Rapport Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$166.71M. For fiscal 2025 it was -$124.08M.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$124.08M | – |
| FY2024 | Dec 31, 2024 | -$82.22M | – |
| FY2023 | Dec 31, 2023 | -$36.07M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$43.89M | – |
| Q2 FY2026 | Jun 30, 2026 | -$60.59M | – |
| Q1 FY2026 | Mar 31, 2026 | -$23.99M | – |
| Q4 FY2025 | Dec 31, 2025 | -$38.24M | – |
| Q3 FY2025 | Sep 30, 2025 | -$29.73M | – |
| Q2 FY2025 | Jun 30, 2025 | -$29.24M | – |
| Q1 FY2025 | Mar 31, 2025 | -$26.86M | – |
| Q4 FY2024 | Dec 31, 2024 | -$23.26M | – |
| Q3 FY2024 | Sep 30, 2024 | -$21.42M | – |
| Q2 FY2024 | Jun 30, 2024 | -$20.59M | – |
| Q1 FY2024 | Mar 31, 2024 | -$16.94M | – |
| Q4 FY2023 | Dec 31, 2023 | -$14.74M | – |
| Q3 FY2023 | Sep 30, 2023 | -$9.54M | – |
See a number that looks wrong?